A Phase 1 interventional study of VSA003 and 0.9% NaCl in Dyslipidemias, Familial Hypercholesterolemia and Hypertriglyceridemia, sponsored by Visirna Therapeutics HK Limited. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Visirna Therapeutics HK Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Dyslipidemias with a site in China — 21 open to participants now, 31 under way, 10 of them phase 3. Dyslipidemias · China.
Among the 73 studies in Dyslipidemias with a site in China, this one is the 52nd largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 1, and was the 47th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →21 of the 73 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–75
China Medical University, China · Sites in China
Ages 50–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 17 · Phase 4 12
First in 2008; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 213 across the 56 interventional studies, 1,000 across the 17 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 73 have an industry lead sponsor. The 10 most frequent:
Visirna Therapeutics HK Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
Visirna Therapeutics HK Limited has 1 study filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
8 of the studies in Dyslipidemias with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07350486First Hospital of China Medical UniversityLLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Dyslipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose of VSA003 by subcutaneous (sc) injections: 50 mg, 100 mg, 200 mg
Drug: VSA003
sterile normal saline (0.9% NaCl) calculated volume to match active treatment
Drug: 0.9% NaCl
sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
placebo
Frequency and severity of adverse event (AE) and serious adverse event (SAE)
safety and tolerability
Time frame: Up to 85±3 days post-dose
Maximum observed concentration (Cmax) of VSA003
pharmacokinetics (PK)
Time frame: Up to 48 hours post dose
Time of occurrence of Cmax (tmax) of VSA003
PK
Time frame: Up to 48 hours post dose
Apparent terminal phase half-life (t1/2) of VSA003
PK
Time frame: Up to 48 hours post dose
Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of VSA003
PK
Time frame: Up to 48 hours post dose
Apparent clearance (CL/F) of VSA003
PK
Time frame: Up to 48 hours post dose
Apparent terminal phase volume of distribution (Vz/F) of VSA003
PK
Time frame: Up to 48 hours post dose
Change of fasting serum ANGPTL3 from pre-dose baseline
PD
Time frame: Up to 85±3 days post-dose
Anti-drug Antibodies (ADA) to VSA003
immunogenecity
Time frame: Up to 85±3 days post-dose
Change of low density lipoprotein cholesterol (LDL-C) from pre-dose baseline
Lipid profile
Time frame: Up to 85±3 days post-dose
Change of total cholesterol (TC) from pre-dose baseline
Lipid profile
Time frame: Up to 85±3 days post-dose
Change of triglyceride (TG) from pre-dose baseline
Lipid profile
Time frame: Up to 85±3 days post-dose
Change of high density lipoprotein cholesterol (HDL-C) from pre-dose baseline
Lipid profile
Time frame: Up to 85±3 days post-dose
Change of fasting glucose from pre-dose baseline
glucose metabolism
Time frame: Up to 85±3 days post-dose
Change of HbA1c from pre-dose baseline
glucose metabolism
Time frame: Up to 85±3 days post-dose
Change of fasting C peptide from pre-dose baseline
glucose metabolism
Time frame: Up to 85±3 days post-dose
Change of fasting insulin from pre-dose baseline
glucose metabolism
Time frame: Up to 85±3 days post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in May 2024, 11 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 11 months is above that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Visirna Therapeutics HK Limited